Business Context and Reporting Period
This Form 8-K Current Report was filed by Aadi Bioscience, Inc. (trading symbol: AADI) on September 27, 2023. The filing primarily addresses Item 5.02 regarding the appointment of a new President and Chief Executive Officer (CEO) and the adoption of a new equity incentive plan.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and corporate governance changes.
Material Changes
- Executive Leadership Change: The Board appointed David J. Lennon, Ph.D., as President and CEO, effective October 2, 2023. He replaces Scott Giacobello, who served as Interim CEO since March 2023. Mr. Giacobello will continue as Chief Financial Officer.
- Board Expansion: The Board size increased from eight to nine directors, with Dr. Lennon appointed as a Class II director.
- New Equity Plan: The Board adopted the 2023 Inducement Equity Incentive Plan, reserving 600,000 shares of Common Stock for issuance to new employees as a material inducement to employment.
Management Commentary, Risks, and Unusual Items
Compensation and Employment Terms
Dr. Lennon's employment agreement includes the following key terms:
- Base Salary: $640,000 annually.
- Annual Bonus: Eligible for up to 60% of base salary based on performance objectives.
- Sign-on Bonus: $240,000 total, consisting of $100,000 cash and $140,000 in Restricted Stock Units (RSUs). The cash portion is subject to clawback if employment ends within 12 months without "Good Reason" or for "Cause."
- Equity Grant: An option to purchase 490,000 shares of Common Stock (the "Lennon Option") under the Inducement Plan. Vesting is 25% on the first anniversary, followed by monthly vesting thereafter, fully vesting over four years.
- Severance:
- Standard Termination: 18 months of severance at 150% of base salary plus COBRA reimbursement.
- Change of Control: Lump sum equal to 150% of (base salary + target bonus), COBRA reimbursement, and 100% accelerated vesting of unvested equity.
- Relocation: Reimbursement for temporary housing and travel between Chicago, Illinois, and New Jersey or California until December 31, 2024.
Background
Dr. Lennon previously served as CEO of Satellite Bio and spent over 15 years at Novartis AG, most recently as President of Novartis Gene Therapies, where he led the development and launch of Zolgensma.
Investor Verification Checklist
- Verify the impact of the new CEO's compensation package on the company's cash burn rate and dilution, specifically the $100,000 immediate cash outlay and the 490,000 share option grant.
- Review the full text of the Executive Employment Agreement (Exhibit 10.2) for specific definitions of "Good Reason" and "Cause" which trigger severance and clawback provisions.
- Confirm the status of the 2023 Inducement Plan (Exhibit 10.3) and the remaining share reserve after the Lennon grant.
- Assess the strategic fit of Dr. Lennon's gene therapy background with Aadi Bioscience's current pipeline and development stage.